Collins Helen Louise Insider Trading Activity
Collins Helen Louise has been net-selling over the last 12 months with 0 purchases and 16 sales across 1 company.
ELVN is the most-traded position with 16 trades. The largest single transaction was a sale of ELVN for $1.4M on Mar 25, 2026.
Performance Scorecard
Forward stock performance after each transaction by Collins Helen Louise. Buy returns measure price movement after open-market purchases; sell-avoided measures the loss avoided after open-market sales. Success rate counts trades where the insider's direction was right.
| PERIOD | AVG BUY RETURN | AVG SELL AVOIDED | SUCCESS RATE | TRADES |
|---|---|---|---|---|
| 30 days | — | -16.8% | 27% | 11 |
| 90 days | — | -25.8% | 0% | 8 |
| 120 days | — | -70.2% | 0% | 5 |
Performance based on stock price movement after each transaction date. Past results do not predict future returns. Not financial advice.
Price & Trades
Pro: Trade MarkersELVN · Enliven Therapeutics, Inc.
🔒 Subscribe to see trade entries
Pro members see exactly when Collins Helen Louise bought and sold ELVN.
Upgrade to ProRecent Trades
| DATE | TICKER | TYPE | SHARES | PRICE | VALUE | Δ OWNED | ROLE | FILING |
|---|---|---|---|---|---|---|---|---|
Jul 17, 2026 | ELVN | Sell | 2,063 | $52.39 | $108K | −7.0% | CHIEF MEDICAL OFFICER | |
Jul 17, 2026 | ELVN | Sell | 459 | $51.55 | $24K | −1.5% | CHIEF MEDICAL OFFICER | |
Jul 17, 2026 | ELVN | Sell | 231 | $50.05 | $12K | −0.8% | CHIEF MEDICAL OFFICER | |
Jul 17, 2026 | ELVN | Sell | 63 | $53.92 | $3K | −0.3% | CHIEF MEDICAL OFFICER | |
Jul 17, 2026 | ELVN | Sell | 2,184 | $53.42 | $117K | −8.0% | CHIEF MEDICAL OFFICER | |
May 18, 2026 | ELVN | Sell | 3,475 | $39.53 | $137K | −11.6% | CHIEF MEDICAL OFFICER | |
May 18, 2026 | ELVN | Sell | 1,302 | $40.25 | $52K | −4.9% | CHIEF MEDICAL OFFICER | |
May 18, 2026 | ELVN | Sell | 223 | $41.21 | $9K | −0.9% | CHIEF MEDICAL OFFICER | |
Apr 17, 2026 | ELVN | Sell | 2,441 | $48.06 | $117K | −8.9% | CHIEF MEDICAL OFFICER | |
Apr 17, 2026 | ELVN | Sell | 140 | $45.81 | $6K | −0.5% | CHIEF MEDICAL OFFICER | |
Apr 17, 2026 | ELVN | Sell | 2,419 | $47.39 | $115K | −8.1% | CHIEF MEDICAL OFFICER | |
Mar 25, 2026 | ELVN | Sell | 40,000 | $35.10 | $1.4M | −61.5% | CHIEF MEDICAL OFFICER | |
Mar 17, 2026 | ELVN | Sell | 5,000 | $27.76 | $139K | −16.7% | CHIEF MEDICAL OFFICER | |
Mar 10, 2026 | ELVN | Sell | 10,129 | $30.19 | $306K | −28.8% | CHIEF MEDICAL OFFICER | |
Mar 9, 2026 | ELVN | Sell | 29,871 | $30.02 | $897K | −54.4% | CHIEF MEDICAL OFFICER | |
Feb 17, 2026 | ELVN | Sell | 45,000 | $26.17 | $1.2M | −64.3% | CHIEF MEDICAL OFFICER |
Top Companies Traded
| TICKER | COMPANY | TRADES | TOTAL VOLUME |
|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | 16 | $4.6M |
Other insiders at Enliven Therapeutics, Inc.
5 other tracked filers at ELVN.